source
- Novo Nordisk’s oral Wegovy sales beat forecasts, boosting shares over 5%BioPharma Dive’s latest visualization series examines how investors reacted to three drug launches highlighted in recent quarterly earnings. Novo Nordisk reported that its oral Wegovy generated 5.…
- Marea Therapeutics reports promising Phase 2b results for MAR001 in hypertriglyceridemiaMarea Therapeutics, which recently merged with oncology firm Lisata Therapeutics, disclosed data from the first part of its phase 2b trial of the drug candidate MAR001. The study enrolled patients…